Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment | Zendy

Paul Devroey | Zendy; Mohamed Aboulghar | Zendy; Juan A. García-Velasco | Zendy; Georg Griesinger | Zendy; Peter Humaidan | Zendy; Efstratios M. Κolibianakis | Zendy; William J. Ledger | Zendy; Candido Tomás | Zendy; B. C. J. M. Fauser | Zendy

Open Access

Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment

Author(s) -

Paul Devroey,

Mohamed Aboulghar,

Juan A. García-Velasco,

Georg Griesinger,

Peter Humaidan,

Efstratios M. Κolibianakis,

William J. Ledger,

Candido Tomás,

B. C. J. M. Fauser

Publication year - 2008

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/den468

Subject(s) - discontinuation , medicine , pregnancy , ovulation induction , agonist , live birth , gynecology , randomized controlled trial , gonadotropin releasing hormone , obstetrics , ovulation , hormone , luteinizing hormone , biology , genetics , receptor

Patients undergoing IVF/ICSI frequently experience substantial treatment burden, risk and psychological distress. These three related elements contribute to a negative patient experience that can lead to treatment discontinuation if pregnancy is not achieved. One approach to minimize these factors is the use of protocols designed to achieve high term, singleton birth rates per IVF treatment started, while improving the patient's welfare. Gonadotrophin-releasing hormone (GnRH) antagonists may be suitable for inclusion in such a protocol. In clinical trial data and meta-analyses, treatment with these agents is associated with similar live birth rates but reduced treatment burden (duration and side effects) and less risk of ovarian stimulation syndrome, compared with GnRH agonist long protocols. GnRH antagonists may also be associated with reduced psychological distress compared with agonists, but so far, the evidence for this is inconclusive. To facilitate the implementation of treatments that optimize the patient's experience, a simple GnRH antagonist protocol for use in predicted normal responders is proposed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research